COMP <GO>
SOLV vs UNH // REVENUE GROWTH (YOY)
Solventum Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SOLV 6
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $84.76 (+0.01%) • MKT CAP: $14.43B
revenue-growth
0.90%
LAST: $404.44 (+1.00%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SOLV VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SOLV | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 88.31% | -34.81 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.70% | 12.38% | +6.32 | SOLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 15.3x | -7.97 | SOLV | /valuation <GO> |
| Free Cash Flow Yield | -0.07% | 6.25% | -6.32 | UNH | /fcf-yield <GO> |
| Operating Margin | 26.20% | 5.32% | +20.88 | SOLV | /operating-margins <GO> |
| Net Profit Margin | 18.70% | 3.53% | +15.17 | SOLV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 0.90% | 3.33% | -2.43 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 3.09 | -0.84 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 55.1 | -6.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.33 | +0.73 | SOLV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 17.7x | -9.24 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.43B | $359.43B | -$345.01B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SOLV REV | UNH REV | SOLV GROSS % | UNH GROSS % | SOLV FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.32B | $447.57B | 53.5% | 88.7% | -$10.0M | $16.07B |
| FY 2024 | $8.25B | $400.28B | 55.6% | 88.3% | $805.0M | $20.70B |
| FY 2023 | $8.20B | $371.62B | — | 89.6% | $1.55B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SOLV // BETA 1.06
UNH // BETA 0.33